Literature DB >> 20433324

Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD).

Shibu P Thomas1, Harpal Singh Nandhra, Anand Jayaraman.   

Abstract

OBJECTIVE: Our aim was to review all the evidence of lamotrigine's effectiveness in treatment resistant depression after at least one failed antidepressant trial.
METHOD: We used a systematic search strategy to identify studies that included adults aged 18-65 years with a diagnosis of unipolar depression who had not responded to at least a 4-week course of a recommended dose of an antidepressant.
RESULTS: We found only one randomized, double blind study that has been published, showing its effectiveness for treatment-resistant depression. In this study, lamotrigine was found statistically superior to placebo on the CGI scale for severity and improvement; however, it was not on the HAM-D (primary end point) and MADRS scales. There were a number of smaller non RCT's which are included.
CONCLUSIONS: There is little evidence to guide the use of lamotrigine for depression that has not responded to a course of antidepressants. Treatment-refractory depression continues to be significant mental health problem and large RCT trials are needed to inform clinical practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20433324     DOI: 10.3109/09638230903469269

Source DB:  PubMed          Journal:  J Ment Health        ISSN: 0963-8237


  9 in total

1.  Comparative Pre-Emptive Analgesic Efficacy Study of Novel Antiepileptic Agents Lamotrigine and Topiramate in Patients Undergoing Major Surgeries at a Tertiary Care Hospital: A Randomized Double Blind Clinical Trial.

Authors:  Ankush Gupta; Uma A Bhosale; Priyank Shah; Radha Yegnanarayan; Shalini Sardesai
Journal:  Ann Neurosci       Date:  2016-09-09

Review 2.  Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.

Authors:  Rebecca L Dean; Tahnee Marquardt; Claudia Hurducas; Styliani Spyridi; Annabelle Barnes; Rebecca Smith; Philip J Cowen; Rupert McShane; Keith Hawton; Gin S Malhi; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2021-10-08

Review 3.  Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression.

Authors:  Chia-Ming Chang; Soichiro Sato; Changsu Han
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

Review 4.  Opioid and Psychostimulant Plasticity: Targeting Overlap in Nucleus Accumbens Glutamate Signaling.

Authors:  Matthew Hearing; Nicholas Graziane; Yan Dong; Mark J Thomas
Journal:  Trends Pharmacol Sci       Date:  2018-01-12       Impact factor: 14.819

5.  An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects.

Authors:  Michele Fornaro; Matteo Martino; Bruna Dalmasso; Salvatore Colicchio; Marzia Benvenuti; Giulio Rocchi; Andrea Escelsior; Giulio Perugi
Journal:  Ann Gen Psychiatry       Date:  2011-09-19       Impact factor: 3.455

Review 6.  Pharmacological approaches to the challenge of treatment-resistant depression.

Authors:  Dawn F Ionescu; Jerrold F Rosenbaum; Jonathan E Alpert
Journal:  Dialogues Clin Neurosci       Date:  2015-06       Impact factor: 5.986

Review 7.  A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders.

Authors:  Marco A Grados; Elizabeth B Atkins; Gabriela I Kovacikova; Erin McVicar
Journal:  Psychol Res Behav Manag       Date:  2015-04-28

8.  A Randomized Double-Blind Placebo-Controlled Study to Compare Preemptive Analgesic Efficacy of Novel Antiepileptic Agent Lamotrigine in Patients Undergoing Major Surgeries.

Authors:  Priyank Shah; Uma A Bhosale; Ankush Gupta; Radha Yegnanarayan; Shalini Sardesai
Journal:  N Am J Med Sci       Date:  2016-02

9.  Severe lamotrigine toxicosis in a dog.

Authors:  Danielle Sawyer; Kathryn Gates
Journal:  Vet Med (Auckl)       Date:  2017-04-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.